Over the last 7 days, the United States market has remained flat, yet over the past 12 months, it has risen by an impressive 20%, with earnings forecasted to grow by 18% annually. In this context of steady growth and positive earnings outlooks, identifying stocks that might be priced below their estimated intrinsic value can present potential opportunities for investors seeking to capitalize on market inefficiencies.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Western Digital (WDC) | $532.10 | $1032.87 | 48.5% |
| Rayonier (RYN) | $21.83 | $42.94 | 49.2% |
| Procore Technologies (PCOR) | $44.72 | $86.77 | 48.5% |
| Natera (NTRA) | $281.27 | $553.62 | 49.2% |
| Genuine Parts (GPC) | $128.67 | $248.48 | 48.2% |
| FatPipe (FATN) | $5.11 | $9.93 | 48.5% |
| Esquire Financial Holdings (ESQ) | $120.50 | $238.84 | 49.5% |
| Betterware de MéxicoP.I. de (BWMX) | $18.17 | $35.99 | 49.5% |
| Beacon Financial (BBT) | $30.23 | $60.24 | 49.8% |
| Amaroq (AMRQ.F) | $1.12 | $2.23 | 49.8% |
Below we spotlight a couple of our favorites from our exclusive screener.
Travere Therapeutics (TVTX)
Overview: Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney and metabolic diseases in the United States, with a market cap of approximately $5.35 billion.
Operations: The company's revenue segment focuses on the development and commercialization of innovative therapies, generating $536.20 million.
Estimated Discount To Fair Value: 35.8%
Travere Therapeutics is trading at a significant discount to its future cash flow value, with shares priced at US$57.85 compared to an estimated value of US$90.16. Despite recent index exclusions, the company shows promising growth prospects, with earnings expected to grow 49% annually and revenue projected to increase by 23.3% per year, outpacing the broader market. Recent FDA approval of FILSPARI expands its addressable market significantly in rare kidney diseases.
- The analysis detailed in our Travere Therapeutics growth report hints at robust future financial performance.
- Delve into the full analysis health report here for a deeper understanding of Travere Therapeutics.
Sonos (SONO)
Overview: Sonos, Inc., along with its subsidiaries, designs, develops, manufactures, and sells audio products and services across the Americas, Europe, the Middle East, Africa, and the Asia Pacific regions with a market cap of approximately $1.62 billion.
Operations: The company's revenue primarily comes from its Audio / Video Products segment, which generated approximately $1.46 billion.
Estimated Discount To Fair Value: 10.8%
Sonos is trading at US$14.10, slightly below its estimated future cash flow value of US$15.80, indicating potential undervaluation. The company's earnings are forecast to grow significantly by 56.9% annually, outpacing the broader market's growth rate of 18.4%. Recent additions to multiple Russell indices and a strategic partnership with Škoda for their electric vehicle highlight growth opportunities, though revenue growth is expected to lag behind the market at 6.9% per year.
- Insights from our recent growth report point to a promising forecast for Sonos' business outlook.
- Take a closer look at Sonos' balance sheet health here in our report.
Capri Holdings (CPRI)
Overview: Capri Holdings Limited is involved in the design, marketing, distribution, and retail of branded apparel, footwear, and accessories for both women and men across various global markets with a market cap of approximately $2.17 billion.
Operations: The company's revenue is primarily derived from its Michael Kors segment, which generated $2.87 billion, and its Jimmy Choo segment, which contributed $600 million.
Estimated Discount To Fair Value: 43.8%
Capri Holdings is trading at US$19.42, well below its estimated future cash flow value of US$34.53, suggesting it may be undervalued based on cash flows. Earnings are expected to grow 25% annually, surpassing the market's growth rate of 18.4%. However, revenue growth is forecasted at only 2% per year, lagging behind the broader market's 12.7%. Recent index reclassifications reflect a shift towards growth-oriented benchmarks despite high debt levels and significant insider selling.
- Our earnings growth report unveils the potential for significant increases in Capri Holdings' future results.
- Unlock comprehensive insights into our analysis of Capri Holdings stock in this financial health report.
Next Steps
- Gain an insight into the universe of 151 Undervalued US Stocks Based On Cash Flows by clicking here.
- Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
- Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Looking For Alternative Opportunities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com